Nuclear epidermal growth factor receptor as a therapeutic target

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal growth factor receptor (EGFR) is a key oncogene implicated in cancer proliferation, metastasis, and therapeutic resistance.
• Current EGFR-targeted therapies, including TKIs and antibodies, are effective against wild-type and mutant EGFR but face challenges like acquired resistance and ineffectiveness in certain cancers such as triple-negative breast cancer (TNBC).

Purpose of the Study:

• To review current EGFR-targeted therapies and explore novel peptide-based therapies designed to block nuclear EGFR (nEGFR).
• To discuss the clinical applications and potential of these novel therapies in oncology, particularly for TNBC where EGFR exhibits nuclear localization.

Main Methods:

• Literature review of existing EGFR-targeted therapies and their mechanisms.
• Exploration of emerging peptide-based therapies targeting the nuclear localization and function of EGFR.
• Analysis of clinical data and potential applications in various cancer types.

Main Results:

• EGFR's role in nuclear functions like transcription, DNA repair, and chemoresistance in TNBC.
• Nuclear localization of EGFR (nEGFR) is associated with metastatic disease and poor prognosis.
• Novel peptide-based therapies demonstrate potential in blocking nEGFR activity.

Conclusions:

• Current EGFR therapies have limitations, especially in TNBC due to nuclear EGFR.
• Targeting nuclear EGFR presents a promising new strategy for overcoming therapeutic resistance.
• Peptide-based therapies offer a novel approach to inhibit nEGFR, with potential for improved cancer treatment outcomes.